Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Four leading healthcare academics in Oxford have received a prestigious national award.

© Shutterstock

The University of Oxford professors have been named National Institute of Health Research (NIHR) Senior Investigators in recognition of their “outstanding contribution to clinical and applied health and social care research”.

The successful candidates are all prominent researchers in the NIHR Oxford Biomedical Research Centre (BRC).

Together, the University of Oxford, Oxford Brookes University, Oxford University Hospitals NHS Foundation Trust and Oxford Health NHS Foundation Trust make up the Oxford Academic Health Science Centre (Oxford AHSC), a partnership that coordinates clinical and academic excellence across the partners.

Senior Investigators are appointed from NIHR Investigators through annual competitions, informed by the advice of an international panel of experts. In total, more than 300 Senior Investigators have now been appointed, with the number of active Senior Investigator awards maintained at around 200. They form part of the NIHR Faculty.

The new NIHR Senior Investigators are:

  • Professor Helen McShane, Director of the NIHR Oxford Biomedical Research Centre; Professor of Vaccinology, Nuffield Department of Medicine
  • Professor Ann Sarah Walker, Professor of Medical Statistics and Epidemiology, Nuffield Department of Medicine
  • Professor Matthew Costa, Professor of Orthopaedic Trauma, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences
  • Professor Richard McManus, Professor of Primary Care, Nuffield Department of Primary Care Health Sciences

As well as the new appointments, three professors who had previously held awards were designated Emeritus Senior Investigators.

Read more (NIHR Oxford BRC website)

Similar stories

Potential for radiotherapy and VTP multimodality therapy for prostate cancer

A recent collaborative study from the University of Oxford has investigated the potential benefit of a combined therapy approach to prostate cancer treatment, using radiotherapy and vascular targeted photodynamic therapy (VTP), which could lead to first-in-man early phase clinical trials.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

First trimester placental scan - Artificial Intelligence in Health and Care Award

A first trimester 3D placental ultrasound scan which can predict fetal growth restriction and pre-eclampsia, could become part of a woman's routine care thanks to a new Artificial Intelligence in Health and Care Award.

Impaired antibody response to COVID-19 vaccination in patients with myeloid blood cancers

Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

Oxford University and partners win government funding to evaluate Paige Prostate Cancer Detection System

A prostate cancer detection software system to help pathologists quickly identify suspicious areas of tissue, developed by Paige, will be investigated in a multicentre clinical study led by Oxford University as part of a successful NHSx Artificial Intelligence Health and Care Award application.

Treating Needle Fears May Reduce COVID-19 Vaccine Hesitancy Rates by 10%

A new large-scale study shows that a quarter of the UK adult population screens positive for a potential injection phobia.